Fast-Tracking the Future
Claire Riches highlights inefficiencies in the current drug approval process, while outlining the role of payers and insurers in shifting toward data-driven approval framework.
In this exclusive PC Podcast interview, Claire Riches, vice president of clinical solutions at Citeline, dives into:
- Specific inefficiencies in the current drug approval system that are the biggest obstacles to faster approvals
- How the FDA can integrate data sources such as real-world data (RWD) to streamline approvals, while maintaining rigorous safety standards
- Advancements in data collection and validation that make RWD a viable tool for drug approvals
- The role payers and insurers should play in this shift toward a more data-driven, flexible approval framework, and how this could impact patient access to innovative treatments
- The likelihood of bipartisan support for reforms that modernize drug approvals with shifting political priorities under HHS Secretary Robert F. Kennedy Jr.
The latest episode of The Pharmaceutical Commerce Podcast is available directly on Audioboom, Spotify, or iHeart.
Recent Videos
Related Content
Multi-Indication Drug Branding in Today’s Pharmaceutical Industry
July 2nd 2025Article
As drug development increasingly targets multiple indications, pharma companies must make strategic branding decisions—balancing regulatory requirements, market dynamics, and patient safety—to choose between single-brand or multi-brand approaches.
